Tech Company Financing Transactions
Cantai Therapeutics Funding Round
On 11/20/2023, Cantai Therapeutics raised Seed funding from Agent Capital, 82VS and Tellus BioVentures.
Transaction Overview
Company Name
Announced On
11/20/2023
Transaction Type
Venture Equity
Amount
Unknown
Round
Seed
Investors
Proceeds Purpose
The company intends to use the funds to develop its drug candidates.
Company Information
Company Status
Private & Independent
Industry
Life Sciences
Mailing Address
3675 Market St 200
Philadelphia, PA 19104
USA
Philadelphia, PA 19104
USA
Phone
Undisclosed
Email Address
Overview
Cantai Therapeutics operates as a developer of drug candidates.Operator of a therapeutics company intended to advance next-generation bispecific antibodies for autoimmune diseases. The company focuses on treating autoimmune and inflammatory disorders by developing cytokine-targeting bispecific antibodies, enabling patients suffering from immune-mediated and autoimmune diseases to receive effective treatments.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Errik Anderson
Co-Founder
Geeta Vemuri
Browse more venture capital transactions:
Prev: 11/20/2023: Torbay Pharmaceuticals venture capital transaction
Next: 11/20/2023: edamama venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on funding rounds that are announced publicly. VC transactions reported here are sourced from company press releases and news coverage. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs